What Is GDM and Why Does It Matter?

Written By GDMCare

The World Health Organization reports that around 21 million women are affected by diabetes in pregnancy globally, of which the majority of cases are GDM. This means around 15-18 million women are diagnosed with GDM each year.

What is GDM? Gestational diabetes mellitus (GDM) is a condition that develops during pregnancy, where blood glucose levels become higher than normal. This happens when hormones produced by the placenta interfere with the body’s ability to use insulin effectively, resulting in insulin resistance. The exact cause of GDM is not fully understood but hormonal changes during pregnancy play a key role in disrupting normal glucose regulation, and in most cases, glucose levels return to normal after delivery.

GDM at a Glance

So, Why Does it Matter?

Risks During Pregnancy and Beyond

The complications of GDM are often manageable, particularly if blood glucose levels are carefully monitored and controlled from the time of diagnosis. If not well managed, GDM can lead to complications during pregnancy and delivery, including:

  • Increased risk of stillbirth

  • Pre-eclampsia (Pregnancy complication due to high blood pressure)

  • Macrosomia (Larger than average baby)

  • Neonatal hypoglycaemia (Low blood sugar in newborn baby)

  • Preterm birth

Despite usually resolving after delivery, GDM can have lasting implications. Women who have been diagnosed with GDM are at a higher risk of developing Type 2 diabetes later in life (with up to 50% going on to develop the condition) and cardiovascular disease for both mother and child. This highlights that GDM is not just a short-term complication, but an early indicator of future health risk.

Rising Pressure on Health Services

Rates of GDM are increasing worldwide, in part due to the rising prevalence of obesity amongst women of reproductive age. Obesity is a major risk factor for GDM, as it contributes to insulin resistance during pregnancy. As more women are diagnosed with GDM, the demand for healthcare support continues to grow. Many require regular blood glucose monitoring, specialist care, and postpartum follow-up to reduce the risk of developing Type 2 diabetes. This increasing demand is placing additional pressure on maternity services, diabetes care, and wider public health systems both during pregnancy and in the years that follow.

Health Inequalities and Disparities

GDM does not affect all women equally; it is more common amongst those from certain ethnic backgrounds, including South Asian, Black, Hispanic, and Middle Eastern populations. It is also more prevalent amongst women living in socioeconomically disadvantaged areas.

This reflects broader inequalities in access to care and support, as some women face barriers to screening, diagnosis, and follow-up during pregnancy. Others may also have limited access to clear health information and the support needed to manage GDM and reduce their risk of developing Type 2 diabetes.

A Window for Early Prevention

GDM represents an important opportunity for early intervention. Pregnancy and the postpartum period provides a key window period to identify women at higher risk of developing Type 2 diabetes. With the right support in place, it is possible to reduce this risk and improve long-term health outcomes. Taking action during this time can have lasting benefits for women, their families, and the wider healthcare system.

Why This Matters Now

What makes GDM different is the opportunity it presents. It is a clear indicator of future Type 2 diabetes at a population level, yet too often care ends at birth. With better screening, clearer information, and sustained postpartum support, there is a real chance to reduce progression to Type 2 diabetes and ease the growing burden on health services.

The issue is also deeply tied to health inequality. Women from South Asian, Black, Hispanic, and Middle Eastern backgrounds, and those living in more deprived communities, are more likely to develop GDM and less likely to receive consistent follow up and support. This reflects wider gaps in access to health information, care, and support. Without targeted action, rising prevalence will deepen existing inequalities in both care and outcomes.

This is a moment to act differently. GDM should catalyse continued support beyond pregnancy, not signal the end of care. Treating it as an early indicator creates an opportunity to prevent Type 2 diabetes, reduce inequalities, and improve outcomes for women and their families.

References

  • American Diabetes Association (2024). Standards of Care in Diabetes.

  • Centers for Disease Control and Prevention (2022). Gestational Diabetes and Type 2 Diabetes.

  • International Diabetes Federation (2021). IDF Diabetes Atlas.

  • Johns Hopkins Medicine (n.d.) Gestational diabetes.

  • National Health Service (2023). Gestational diabetes.

  • National Institute for Health and Care Excellence (2020). Diabetes in pregnancy: management (NG3).

  • National Institute of Diabetes and Digestive and Kidney Diseases (2022). Gestational Diabetes.

  • UK Health Security Agency. Health inequalities and obesity reports.

  • World Health Organization (2013). Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy.

  • World Health Organization (2021). Obesity and overweight.

  • World Health Organization (2025). Hyperglycaemia in pregnancy guidance.

  • World Health Organization. Diabetes in pregnancy.

  • World Health Organization. Diabetes prevention and control.

  • World Health Organization. Social determinants of health.

  • Wang, H., et al. (2022). Estimation of global and regional gestational diabetes prevalence. Diabetes Research and Clinical Practice.

GDMCare